Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Ceapro stock

CZO.V
CA1499071076
931278

Price

7.91
Today +/-
+0
Today %
+0 %

Ceapro stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Ceapro stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Ceapro stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Ceapro stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Ceapro's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Ceapro Stock Price History

DateCeapro Price
7/31/20247.91 undefined
7/30/20247.85 undefined

Ceapro Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Ceapro, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ceapro from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ceapro’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ceapro. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ceapro’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ceapro’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ceapro’s growth potential.

Ceapro Revenue, EBIT and net profit per share

DateCeapro RevenueCeapro EBITCeapro Net Income
2024e24.99 M undefined0 undefined0 undefined
20239.63 M undefined-6.31 M undefined-4.71 M undefined
202218.84 M undefined5.44 M undefined4.4 M undefined
202117.2 M undefined3.25 M undefined3.37 M undefined
202015.12 M undefined2.29 M undefined1.86 M undefined
201912.88 M undefined-380,960 undefined-1.13 M undefined
201811.59 M undefined191,810 undefined-315,540 undefined
201712.93 M undefined2.74 M undefined-958,280 undefined
201613.67 M undefined6.19 M undefined3.62 M undefined
201510.67 M undefined3.83 M undefined4.92 M undefined
20148.89 M undefined2.06 M undefined1.59 M undefined
20136.52 M undefined510,000 undefined180,000 undefined
20125.17 M undefined-420,000 undefined-540,000 undefined
20115.79 M undefined760,000 undefined580,000 undefined
20105.58 M undefined370,000 undefined500,000 undefined
20094.37 M undefined-360,000 undefined-70,000 undefined
20084.23 M undefined-2.12 M undefined-3.6 M undefined
20073.45 M undefined-1.26 M undefined-1.39 M undefined
20063.31 M undefined-290,000 undefined-270,000 undefined
20052.68 M undefined-250,000 undefined-60,000 undefined
20041.96 M undefined-240,000 undefined-400,000 undefined

Ceapro Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e
000112123344555681013121112151718924
-----100.00-50.00100.0050.00-33.33-25.00--20.0033.3325.0030.00-7.69-8.339.0925.0013.335.88-50.00166.67
---300.00300.0050.00100.0050.0033.3333.3325.0050.0040.0060.0040.0050.0050.0070.0069.2358.3354.5541.6746.6758.8261.1133.3312.50
00000111111223234797657101130
-1400000000-1-30000014300-1134-40
----------200.00------300.00-25.00----200.00200.0033.33-200.00-
18.0521.2321.6227.1532.5435.3834.7636.3437.1942.3447.0549.5858.2256.6460.2860.2860.965.271.3375.3476.277.1978.1478.5978.5878.270
---------------------------
Details

Keystats

Revenue and Growth

The Ceapro Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Ceapro is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (k)GOODWILL (k)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                   
0.010.020.040.050.030.250.10.440.311.280.020.120.190.590.271.950.271.689.156.171.841.865.377.7813.818.84
0.080.090.070.080.280.510.380.980.630.710.550.150.570.470.450.250.420.540.571.253.023.662.022.092.820.17
5000000000000000280210.9124.13122.42213.5246.946.81102.2345.8564.81216.76
0.010.050.060.090.060.120.350.230.160.160.410.520.280.690.790.320.681.241.181.090.710.671.212.323.765.31
3010106020301209018013080607012086034061.5259.56371.95277.6518.22178.91348.85162.92135.13310.19
0.180.170.180.280.390.910.951.741.282.281.060.851.111.872.373.141.653.8511.3996.146.419.0512.4120.5914.85
0.120.120.110.10.270.350.720.680.612.262.21.91.691.521.431.855.969.8714.3217.3817.9519.7618.5917.516.215.42
00000000000000000000000000
00000000000000000603.3487.34607.7607.7607.7607.7766.63854.9984.2
18000000000030302040707036.2933.3330.37517.1424.4421.4818.5115.5512.599.63
0000000000000000000218.61000000
0000000.0600.170.050000.7500.030.041.350.160.090.610.460.960.360.080.18
0.30.120.110.10.270.350.780.680.782.312.231.931.712.311.51.956.0411.861518.8119.1920.8620.1718.6417.1516.6
0.480.290.290.380.661.261.732.422.064.593.292.782.824.183.875.097.6815.726.3927.8125.3227.2729.2231.0537.7331.45
                                                   
43.8543.9144.3345.961.41.9922.422.515.025.025.485.776.326.326.326.576.814.8615.5716.3216.416.5116.5616.6916.72
0000000.120.110.130.260.370.480.510.40.430.50.511.033.874.274.54.654.684.684.714.96
-44.94-45.81-46.72-47.1-2.05-1.61-2-2.06-2.33-3.72-7.32-7.39-6.89-6.2-6.73-6.56-4.96-0.063.672.712.391.263.126.4810.886.17
00000000000606000-200106.200000000
00000000000000000000000000
-1.09-1.9-2.39-1.14-0.650.380.120.470.311.56-1.93-1.37-0.550.520.020.242.117.8822.422.5423.2122.3124.3127.7232.2927.86
1.261.641.750.520.450.540.710.280.340.491.150.850.860.620.580.991.792.010.970.980.951.291.070.681.731.34
00000000000010903018000000001000
0000000.080.230.110.111.710.370.060.571.70.360.161.270.492.15000000
26023013020200120804000000000000000000
0.010.250.330.080.150.090.150.140.170.250.590.90.990.230.260.680.841.931.080.930.410.450.320.290.370.4
1.532.122.210.620.620.631.060.730.660.853.452.121.921.512.572.212.795.22.534.071.361.741.390.982.11.74
0.040.080.470.830.590.150.470.440.41.51.371.671.080.931.092.512.632.511.460.590.232.842.652.362.251.85
000000000000000000.1100.60.520.380.8701.10
0000.060.080.110.070.790.720.680.40.360.361.220.220.130000000000
0.040.080.470.890.670.260.541.231.122.181.772.031.442.151.312.642.632.621.461.20.753.223.522.363.341.85
1.572.22.681.511.290.891.61.961.783.035.224.153.363.663.884.855.427.833.995.262.114.964.913.345.453.59
0.480.30.290.370.641.271.722.432.094.593.292.782.814.183.95.097.5315.726.3927.8125.3227.2729.2231.0637.7331.45
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Ceapro provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Ceapro's financial health and stability.

Assets

Ceapro's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Ceapro must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Ceapro after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Ceapro's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (k)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
-1400000000-1-30000014300-1124
0000000000000000000001,0001,0001,0001,000
0000000000000000001,000000001,000
00000000002-100000-200-2000-1
12000000000000000000200000
0000000000000000000000000
000000000000000001,0000000000
-200000000-1-1000002341-20436
000000000-100000-2-4-4-4-4-10000
000000000-100000-2-4-3-6-4-10000
000000000000000000-1000000
0000000000000000000000000
-1,000000000001,000000001,00000-1,000-1,00000000
30000000020000000010000000
2000000003010003008000000
0000000000000001,000000000000
0000000000000000000000000
0000000000-100001-117-2-40326
-2.58-0.39-0.79-0.74-0.3-0.06-0.57-0.550.09-2.86-1.42-1.020.270.67-0.36-1.81-2.18-0.220.04-2.45-3.30.543.912.86.3
0000000000000000000000000

Ceapro stock margins

The Ceapro margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ceapro. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ceapro.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ceapro's sales revenue. A higher gross margin percentage indicates that the Ceapro retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ceapro's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ceapro's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ceapro's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ceapro. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ceapro's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ceapro Margin History

Ceapro Gross marginCeapro Profit marginCeapro EBIT marginCeapro Profit margin
2024e41.07 %0 %0 %
202341.07 %-65.51 %-48.89 %
202258.48 %28.9 %23.34 %
202160.87 %18.89 %19.57 %
202050.41 %15.15 %12.27 %
201942.28 %-2.96 %-8.79 %
201852.95 %1.65 %-2.72 %
201756.26 %21.18 %-7.41 %
201668.4 %45.28 %26.47 %
201565.89 %35.87 %46.14 %
201453.58 %23.21 %17.93 %
201347.55 %7.82 %2.76 %
201247.39 %-8.12 %-10.44 %
201156.13 %13.13 %10.02 %
201045.52 %6.63 %8.96 %
200948.51 %-8.24 %-1.6 %
200837.59 %-50.12 %-85.11 %
200747.83 %-36.52 %-40.29 %
200657.4 %-8.76 %-8.16 %
200561.19 %-9.33 %-2.24 %
200471.43 %-12.24 %-20.41 %

Ceapro Stock Sales Revenue, EBIT, Earnings per Share

The Ceapro earnings per share therefore indicates how much revenue Ceapro has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Ceapro earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ceapro's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ceapro’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ceapro's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ceapro Revenue, EBIT and net profit per share

DateCeapro Sales per ShareCeapro EBIT per shareCeapro Earnings per Share
2024e0.32 undefined0 undefined0 undefined
20230.12 undefined-0.08 undefined-0.06 undefined
20220.24 undefined0.07 undefined0.06 undefined
20210.22 undefined0.04 undefined0.04 undefined
20200.19 undefined0.03 undefined0.02 undefined
20190.17 undefined-0 undefined-0.01 undefined
20180.15 undefined0 undefined-0 undefined
20170.17 undefined0.04 undefined-0.01 undefined
20160.19 undefined0.09 undefined0.05 undefined
20150.16 undefined0.06 undefined0.08 undefined
20140.15 undefined0.03 undefined0.03 undefined
20130.11 undefined0.01 undefined0 undefined
20120.09 undefined-0.01 undefined-0.01 undefined
20110.1 undefined0.01 undefined0.01 undefined
20100.1 undefined0.01 undefined0.01 undefined
20090.09 undefined-0.01 undefined-0 undefined
20080.09 undefined-0.05 undefined-0.08 undefined
20070.08 undefined-0.03 undefined-0.03 undefined
20060.09 undefined-0.01 undefined-0.01 undefined
20050.07 undefined-0.01 undefined-0 undefined
20040.06 undefined-0.01 undefined-0.01 undefined

Ceapro business model

Ceapro Inc is an innovative biotechnology company based in Edmonton, Canada. The company was founded in 1997 and has since specialized in the development of natural, biological ingredients from plants. It is listed on the Toronto Stock Exchange and has become a key player in the field of natural-based medicine and cosmetics in recent years. Ceapro's business model is based on the research and production of active compounds from plant-based raw materials. The company employs gentle extraction methods that preserve the effectiveness of the ingredients and enable environmentally friendly production. Ceapro collaborates closely with research and industry to ensure the best possible effectiveness and applicability of its products. The company's products are divided into various segments tailored to the needs of customers. One important segment is medicine, where Ceapro focuses on the development of herbal remedies. The company has already developed some promising products in this area, which can be used, for example, for inflammation, pain, or diabetes. Another important segment of Ceapro is cosmetics, where the company researches and produces natural ingredients for skin and hair care. These products are known for their high effectiveness, tolerability, and environmental friendliness. One of the company's most famous products is Avenanthramide, an ingredient derived from oats that offers anti-aging and anti-inflammatory properties. Ceapro also places special emphasis on the development of digestive-aid ingredients that can be used in the food industry. The company relies on plant enzymes and compounds that help support and relieve the digestive system. The use of natural ingredients ensures high tolerability and usability. Over the course of its history, Ceapro Inc has already won numerous awards and prizes that confirm the high quality of its products and the company's innovative power. For example, the company has been repeatedly honored with the Alberta Venture Fast Growth 50 Award and also received the Environmental Stewardship Award from the Edmonton Chamber of Commerce. Ceapro is not only an innovative biotechnology company specializing in the research and production of plant-based ingredients but also an important player in the fields of medicine and cosmetics. The company employs gentle extraction methods and collaborates closely with research and industry to achieve the best possible effectiveness and applicability. The different products are divided into the segments of medicine, cosmetics, and food and are known for their high effectiveness, tolerability, and environmental friendliness. Ceapro is one of the most popular companies on Eulerpool.com.

Ceapro SWOT Analysis

Strengths

Ceapro Inc has a strong research and development team that continually innovates and creates new products, giving the company a competitive edge in the market.

The company has a diverse product portfolio, offering a wide range of high-quality natural ingredients for various industries, including pharmaceuticals, cosmetics, and nutraceuticals.

Ceapro Inc has established strong relationships with key suppliers and distributors, allowing them to maintain a consistent supply chain and reach customers globally.

The company has a solid financial position, with steady revenue growth and profitability, enabling them to invest in research and development activities and expand their operations.

Weaknesses

Ceapro Inc relies heavily on a limited number of major customers, which poses a risk to the company if it were to lose any of these key accounts.

The company's global presence is relatively small compared to some competitors, limiting their market reach and potential for growth.

Ceapro Inc faces the challenge of maintaining consistent product quality and ensuring efficient manufacturing processes to meet market demand.

Opportunities

The rise in demand for natural and sustainable ingredients in various industries provides Ceapro Inc with an opportunity to capitalize on their expertise in producing such products.

Expansion into emerging markets, such as Asia-Pacific and Latin America, can help Ceapro Inc tap into new customer segments and further grow their business.

Collaborations with academic institutions and research organizations can enhance Ceapro Inc's research capabilities and lead to the development of innovative and differentiated products.

Threats

Intense competition in the natural ingredients market can erode Ceapro Inc's market share and pricing power if they fail to differentiate themselves effectively.

Economic downturns and fluctuations in currency exchange rates may impact the company's profitability, especially if it heavily relies on export markets.

Changes in regulations and compliance requirements in the markets Ceapro Inc operates in can pose challenges and increase costs for the company.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Ceapro Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Ceapro historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Ceapro shares outstanding

The number of shares was Ceapro in 2023 — This indicates how many shares 78.273 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Ceapro earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ceapro's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ceapro’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ceapro's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ceapro stock splits

In Ceapro's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Ceapro.

Ceapro latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2007-0.01 -0.01  (2.91 %)2007 Q4
1

Ceapro shareholders

%
Name
Stocks
Change
Date
2.27112 % Gagnon (Gilles R)1,778,06239,0622/9/2024
1.46460 % Rourke (Glenn)1,146,63604/19/2023
0.12975 % Li (William W. M.D.)101,57902/9/2024
0.10005 % Kosciessa (Ulrich)78,32702/9/2024
0.04151 % Prefontaine (Stacy)32,50032,5002/9/2024
1

Ceapro Executives and Management Board

Mr. Gilles Gagnon

Ceapro Chief Executive Officer, Director (since 2007)
Compensation 560,000

Ms. Stacy Prefontaine

Ceapro Chief Financial Officer
Compensation 232,988

Mr. Ronald Miller

Ceapro Independent Chairman of the Board
Compensation 96,060

Ms. Genevieve Foster

Ceapro Independent Director
Compensation 92,378

Dr. William Li

(60)
Ceapro Independent Director
Compensation 59,566
1
2

Ceapro Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,610,170,680,230,67
SupplierCustomer0,580,590,530,740,09
SupplierCustomer0,47 0,570,700,73
SupplierCustomer0,460,080,38-0,46-0,44
SupplierCustomer0,460,580,200,54-0,07
SupplierCustomer-0,030,130,250,730,84
SupplierCustomer-0,39-0,250,550,710,49
SupplierCustomer-0,64-0,680,080,410,06
SupplierCustomer-0,78-0,820,040,560,76
SupplierCustomer-0,88-0,830,020,730,89
1

Most common questions regarding Ceapro

What values and corporate philosophy does Ceapro represent?

Ceapro Inc represents values of excellence, innovation, and sustainability. As a biotechnology company, Ceapro is dedicated to developing and commercializing active ingredients derived from natural resources for personal care, cosmetics, and pharmaceutical industries. The corporate philosophy of Ceapro emphasizes a commitment to cutting-edge research, high-quality products, and environmental responsibility. By combining advanced technology with a deep understanding of natural materials, Ceapro aims to provide effective and sustainable solutions to its clients. With its focus on innovation and dedication to eco-friendly practices, Ceapro Inc stands as a leading player in the biotechnology industry.

In which countries and regions is Ceapro primarily present?

Ceapro Inc is primarily present in Canada and the United States.

What significant milestones has the company Ceapro achieved?

Ceapro Inc has achieved significant milestones throughout its journey. The company successfully developed and commercialized its flagship product, Avenanthramides, which has gained recognition for its numerous health benefits. Additionally, Ceapro Inc has built a strong research and development platform, leading to the creation of innovative products derived from natural sources. The company has also collaborated with renowned academic institutions and established partnerships with leading players in the industry, enhancing its global presence. With a dedicated focus on sustainability and continuous growth, Ceapro Inc remains committed to delivering high-quality, nature-based solutions to improve the health and well-being of consumers.

What is the history and background of the company Ceapro?

Ceapro Inc. is a Canadian biotechnology company that specializes in developing and manufacturing innovative extracts and active ingredients derived from natural sources. Established in 1997, Ceapro has a rich history of over two decades in the biopharmaceutical industry. The company focuses on utilizing its patented technology to transform renewable resources into high-value functional products. Ceapro's expertise lies in the production of unique biopolymers, such as beta glucan, as well as other innovative solutions for human and animal health. With a commitment to sustainability and scientific excellence, Ceapro continues to thrive as a leader in the biotechnology sector.

Who are the main competitors of Ceapro in the market?

Some major competitors of Ceapro Inc in the market include Active Organics, Ashland LLC, and Croda International.

In which industries is Ceapro primarily active?

Ceapro Inc is primarily active in the biotechnology industry.

What is the business model of Ceapro?

The business model of Ceapro Inc revolves around the development and commercialization of innovative natural products derived from oats and other plant sources. Ceapro specializes in the extraction and purification of active ingredients for the pharmaceutical, cosmetic, and human health markets. By leveraging its proprietary technologies, Ceapro harnesses the power of nature to create high-value products that provide sustainable and renewable solutions. With a strong focus on research and development, Ceapro aims to deliver unique and effective products for a wide range of applications, catering to the growing demand for natural and environmentally friendly alternatives.

What is the P/E ratio of Ceapro 2024?

The Ceapro P/E ratio is 0.

What is the P/S ratio of Ceapro 2024?

The Ceapro P/S ratio is 24.78.

What is the Quality Investing of Ceapro?

The Quality Investing for Ceapro is 2/10.

What is the revenue of Ceapro 2024?

The expected Ceapro revenue is 24.99 M CAD.

How high is the profit of Ceapro 2024?

The profit cannot currently be calculated for Ceapro.

What is the business model of Ceapro

Ceapro Inc is a Canadian company specialized in the development and manufacturing of natural health and beauty products from plant and marine sources. The company is headquartered in Edmonton, Alberta, and has state-of-the-art production facilities, research and development departments, as well as sales and marketing teams in North America, Europe, and Asia. Ceapro offers a wide range of products that are highly regarded worldwide for their high quality and effectiveness. These include products from five different business units: 1. Health and Wellness: This business unit includes products such as Beta-Glucan, a natural immune stimulant used mainly in the pharmaceutical and food industry. Ceapro also produces Chitosan, a fiber derived from crabs and shrimps, used in wound healing, cosmetics, and dietary supplements. 2. Cosmeceuticals: Under this unit, Ceapro offers skincare products based on natural ingredients such as Beta-Glucan and Avenanthramid. The company provides an anti-aging product line, such as HyaClear, which is based on Hyaluronic Acid. 3. Functional Food: Ceapro offers natural food additives under this unit that provide health benefits, such as Beta-Glucan or plant fibers that support digestion. 4. Veterinary Health: Ceapro also produces a range of veterinary products, including Beta-Glucan-based products to strengthen pets' immune systems and Chitosan-based wound care products. 5. Active Ingredients: Under this business unit, Ceapro supplies natural active ingredients to the pharmaceutical and cosmetics industries, which can be used in prescription products, over-the-counter medications, and cosmetics. Ceapro employs an integrated approach that extends from research and development to the production process to ensure high quality and effectiveness of its products. The company relies on unique and patented processes to extract active ingredients from plant and marine sources and consistently invests in research and development to develop innovative products that meet market needs. The company is led by an experienced management team composed of seasoned scientists and business professionals who share Ceapro's vision of improving people's lives by offering natural products of the highest quality. To effectively market its products, Ceapro relies on a global distribution strategy that includes a comprehensive presence in North America, Europe, and Asia. The company maintains strong partnerships with several companies in various industries, including animal health, food, pharmaceutical, and cosmetics industries. Conclusion Ceapro Inc is a leading company in the development and production of natural health and beauty products from plant and marine sources. The company specializes in five business units that encompass a wide range of products, from food additives to animal health products. Ceapro employs an integrated research and development strategy to develop innovative products that meet market needs. The company has a broad global distribution strategy and is dedicated to offering natural products of the highest quality to improve people's lives.

What is the Ceapro dividend?

Ceapro pays a dividend of 0 CAD distributed over payouts per year.

How often does Ceapro pay dividends?

The dividend cannot currently be calculated for Ceapro or the company does not pay out a dividend.

What is the Ceapro ISIN?

The ISIN of Ceapro is CA1499071076.

What is the Ceapro WKN?

The WKN of Ceapro is 931278.

What is the Ceapro ticker?

The ticker of Ceapro is CZO.V.

How much dividend does Ceapro pay?

Over the past 12 months, Ceapro paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ceapro is expected to pay a dividend of 0 CAD.

What is the dividend yield of Ceapro?

The current dividend yield of Ceapro is .

When does Ceapro pay dividends?

Ceapro pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ceapro?

Ceapro paid dividends every year for the past 0 years.

What is the dividend of Ceapro?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ceapro located?

Ceapro is assigned to the 'Commodities' sector.

Wann musste ich die Aktien von Ceapro kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ceapro from 12/1/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 12/1/2024.

When did Ceapro pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Ceapro in the year 2023?

In the year 2023, Ceapro distributed 0 CAD as dividends.

In which currency does Ceapro pay out the dividend?

The dividends of Ceapro are distributed in CAD.

All fundamentals about Ceapro

Our stock analysis for Ceapro Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ceapro Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.